Article ; Online: A cautionary tale: an evaluation of the performance of treatment switching adjustment methods in a real world case study.
BMC medical research methodology
2024 Volume 24, Issue 1, Page(s) 17
Abstract: Background: Treatment switching in randomised controlled trials (RCTs) is a problem for health technology assessment when substantial proportions of patients switch onto effective treatments that would not be available in standard clinical practice. ... ...
| Abstract | Background: Treatment switching in randomised controlled trials (RCTs) is a problem for health technology assessment when substantial proportions of patients switch onto effective treatments that would not be available in standard clinical practice. Often statistical methods are used to adjust for switching: these can be applied in different ways, and performance has been assessed in simulation studies, but not in real-world case studies. We assessed the performance of adjustment methods described in National Institute for Health and Care Excellence Decision Support Unit Technical Support Document 16, applying them to an RCT comparing panitumumab to best supportive care (BSC) in colorectal cancer, in which 76% of patients randomised to BSC switched onto panitumumab. The RCT resulted in intention-to-treat hazard ratios (HR) for overall survival (OS) of 1.00 (95% confidence interval [CI] 0.82-1.22) for all patients, and 0.99 (95% CI 0.75-1.29) for patients with wild-type KRAS (Kirsten rat sarcoma virus). Methods: We tested several applications of inverse probability of censoring weights (IPCW), rank preserving structural failure time models (RPSFTM) and simple and complex two-stage estimation (TSE) to estimate treatment effects that would have been observed if BSC patients had not switched onto panitumumab. To assess the performance of these analyses we ascertained the true effectiveness of panitumumab based on: (i) subsequent RCTs of panitumumab that disallowed treatment switching; (ii) studies of cetuximab that disallowed treatment switching, (iii) analyses demonstrating that only patients with wild-type KRAS benefit from panitumumab. These sources suggest the true OS HR for panitumumab is 0.76-0.77 (95% CI 0.60-0.98) for all patients, and 0.55-0.73 (95% CI 0.41-0.93) for patients with wild-type KRAS. Results: Some applications of IPCW and TSE provided treatment effect estimates that closely matched the point-estimates and CIs of the expected truths. However, other applications produced estimates towards the boundaries of the expected truths, with some TSE applications producing estimates that lay outside the expected true confidence intervals. The RPSFTM performed relatively poorly, with all applications providing treatment effect estimates close to 1, often with extremely wide confidence intervals. Conclusions: Adjustment analyses may provide unreliable results. How each method is applied must be scrutinised to assess reliability. |
|---|---|
| MeSH term(s) | Humans ; Panitumumab/therapeutic use ; Proto-Oncogene Proteins p21(ras) ; Treatment Switching ; Computer Simulation ; Probability ; Randomized Controlled Trials as Topic |
| Chemical Substances | Panitumumab (6A901E312A) ; Proto-Oncogene Proteins p21(ras) (EC 3.6.5.2) |
| Language | English |
| Publishing date | 2024-01-22 |
| Publishing country | England |
| Document type | Journal Article |
| ZDB-ID | 2041362-2 |
| ISSN | 1471-2288 ; 1471-2288 |
| ISSN (online) | 1471-2288 |
| ISSN | 1471-2288 |
| DOI | 10.1186/s12874-024-02140-6 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.